Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | TOP2A | P11388 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159326 | 0.99 | KDM4E (0.82) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL9145542 | 0.97 | KDM4E (0.82) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL17510023 | 0.91 | KDM4E (0.79) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL30811901 | 0.91 | KDM4E (0.73) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10566738 | 0.91 | KDM4E (0.73) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL1155029 | 0.90 | KDM4E (0.78) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10736589 | 0.90 | KDM4E (0.79) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10374013 | 0.90 | KDM4E (0.79) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10373193 | 0.89 | KDM4E (0.74) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10374148 | 0.89 | KDM4E (0.74) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | COYOTE PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-8034817-B2 | Inhalation of quinolinonecarboxylic acid compound | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-11 | — | — | US | disclosed |
| CN-1157389-C | Quinoline carboxylic acid derivative or salt thereof | ������ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| CN-1358183-A | Quinolinecarboxylic acid derivative or salts thereof | WAKUZAGA PHARMACEUTICAL CO LTD (JP) | 2002-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275281-A1 | Geranylgeranyl acetone and derivatives thereof for intranasal administration | GGPS1, NAA50, GAP43 | KDM4E 4689/4885ALDH1A1 1579/4885LMNA 2669/4885 |
| US-20140275091-A1 | Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery | FNTA, GGPS1, GNPAT | KDM4E 4505/4885ALDH1A1 380/4885LMNA 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.